Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
Launched by DAVID M. RITTER · Nov 28, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry) is a study aimed at collecting important information about pregnant women who have Tuberous Sclerosis Complex (TSC) or Lymphangioleiomyomatosis (LAM) and their babies. This research helps us understand how these conditions might affect pregnancy and the health of the child. The study is currently looking for female participants who are pregnant and meet specific criteria, such as having a confirmed diagnosis of TSC or LAM, or if their baby has a chance of being affected by TSC.
If you participate in this registry, you can expect to share your health information and experiences during your pregnancy. The study will help doctors and researchers learn more about TSC and LAM, which could lead to better care for other women and children in the future. It's important to know that this is an observational study, meaning that participants will be monitored without any experimental treatments being given. Your involvement could contribute significantly to understanding these conditions better!
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • A pregnant woman with a clinical or genetic diagnosis of TSC as determined by the 2021 Consensus Guidelines (1)
- • A pregnant woman with a diagnosis of LAM
- • A pregnant woman with a variant of uncertain significance in TSC 1 or TSC 2
- • A pregnant woman who is pregnant and the fetus has a 50% chance of TSC as deemed by the PI or Sub-Is
- • A pregnant woman whose fetus is found to have concern for TSC secondary to rhabdomyomas, tubers, or congenital subependymal giant cell astrocytoma.
- • An infant born to an enrolled individual.
- Exclusion Criteria:
- • A pregnant woman without TSC who has used preimplantation genetic testing for TSC unless qualifies under inclusion criteria #4.
- • Infants diagnosed with TSC whose birth mother was not enrolled.
About David M. Ritter
David M. Ritter is a dedicated clinical trial sponsor with a commitment to advancing medical research and improving patient outcomes. With extensive experience in the healthcare sector, Mr. Ritter focuses on facilitating innovative clinical studies that explore new therapies and treatment options across various medical fields. His strategic approach emphasizes collaboration with regulatory bodies, healthcare professionals, and research institutions to ensure the highest standards of quality and integrity in clinical trials. By prioritizing patient safety and ethical practices, David M. Ritter aims to contribute significantly to the development of groundbreaking medical solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cincinnati, Ohio, United States
Patients applied
Trial Officials
David M Ritter, MD, PhD
Principal Investigator
Children's Hospital Medical Center, Cincinnati
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported